Cargando…

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies

Almorexant, a dual orexin receptor antagonist, was investigated for the treatment of insomnia. The following observations initiated further formulation development: the active pharmaceutical ingredient (API) was sticking to the apparatus used during tablet compression; almorexant has an absolute bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dingemanse, Jasper, Gehin, Martine, Cruz, Hans Gabriel, Hoever, Petra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010641/ https://www.ncbi.nlm.nih.gov/pubmed/24812492 http://dx.doi.org/10.2147/DDDT.S62118

Ejemplares similares

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant
por: Dietrich, Hendrik, et al.
Publicado: (2010)

The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats
por: Morairty, Stephen R., et al.
Publicado: (2014)

The Dual Orexin/Hypocretin Receptor Antagonist, Almorexant, in the Ventral Tegmental Area Attenuates Ethanol Self-Administration
por: Srinivasan, Subhashini, et al.
Publicado: (2012)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma
por: Dayot, Stéphanie, et al.
Publicado: (2018)

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
por: Hsin, Chih-hsuan, et al.
Publicado: (2023)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
por: Berger, Benjamin, et al.
Publicado: (2023)

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders
por: Gehin, Martine, et al.
Publicado: (2020)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
por: Anderson, Rachel I., et al.
Publicado: (2014)

Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
por: Hoever, P, et al.
Publicado: (2012)

Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists
por: Gozzi, Alessandro, et al.
Publicado: (2011)

Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
por: Merlo Pich, Emilio, et al.
Publicado: (2014)

Functional cardiac orexin receptors: role of orexin-B/orexin 2 receptor in myocardial protection
por: Patel, Vanlata H., et al.
Publicado: (2018)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Differential sleep-promoting effects of dual orexin receptor antagonists and GABA(A) receptor modulators
por: Gotter, Anthony L, et al.
Publicado: (2014)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

Biocomparison of Three Formulations of the S1P(1) Receptor Modulator Ponesimod in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2015)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice
por: Duncan, Marilyn J., et al.
Publicado: (2019)

The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking
por: Khoo, Shaun Yon-Seng, et al.
Publicado: (2017)

Neuropeptide Y-Induced Orexigenic Action Is Attenuated by the Orexin Receptor Antagonist in Bullfrog Larvae
por: Matsuda, Kouhei, et al.
Publicado: (2017)

Synthesis and biological activity evaluation of azacycloheptane sulfonamide derivatives as potential orexin receptor antagonists
por: Guo, Bin, et al.
Publicado: (2020)

Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
por: Zhou, Mengzhen, et al.
Publicado: (2023)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
por: Rocha, Rebeka Bustamante, et al.
Publicado: (2023)

Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity
por: Turku, Ainoleena, et al.
Publicado: (2017)

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
por: Gotter, Anthony L, et al.
Publicado: (2013)

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy
por: Fitch, Thomas E., et al.
Publicado: (2014)

Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2017)

Orexin Receptor Competitive Antagonists: A Novel target of the Sedative and hypnotics drugs for the pharmacotherapy of Insomnia
por: Banerjee, Indrajit
Publicado: (2018)

Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise
por: Martin, Tristan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0s31nro8lrjne5v74i8bes9ufm